Compuesto Regulado por la FDA
Este compuesto es aprobado o regulado por la FDA. Comprar sin una receta válida puede violar la ley federal. Verifica todos los requisitos legales en tu jurisdicción.
Liraglutide
Victoza / Saxenda
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, sharing 97% homology with native human GLP-1. It is FDA-approved as Victoza for type 2 diabetes management and as Saxenda for chronic weight management. As a once-daily injection, it was the first long-acting GLP-1 analog to achieve widespread clinical use and served as the predecessor to semaglutide.
Mecanismo de Acción
GLP-1 receptor agonist with 97% homology to native GLP-1. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.
Protocolos de Investigación
Para propósitos de investigación solo. No es asesoramiento médico.
Weight management protocols use up to 3.0mg daily with weekly 0.6mg dose escalation.
Notas de Investigación
Clinical Research Status
Liraglutide holds full FDA approval for two indications: type 2 diabetes (Victoza, approved 2010) and obesity (Saxenda, approved 2014). The LEADER cardiovascular outcomes trial demonstrated a 13% reduction in major adverse cardiovascular events. It remains widely prescribed though newer weekly agents are increasingly preferred.
Key Published Findings
The SCALE trials demonstrated 5-8% mean body weight loss versus placebo across multiple populations. Liraglutide has been shown to reduce HbA1c by 1.0-1.5% in type 2 diabetes, with additional benefits in beta-cell preservation. Post-marketing data from over a decade of use provides one of the most robust safety databases among GLP-1 agonists.
Safety Profile
The most common adverse effects are gastrointestinal: nausea, vomiting, and diarrhea, typically diminishing over 4-8 weeks of dose titration. A boxed warning exists for medullary thyroid carcinoma risk based on rodent studies, though human epidemiological data has not confirmed this risk. Pancreatitis cases have been reported rarely, and the drug is contraindicated in patients with personal or family history of MTC.
Comparison to Related Compounds
Compared to semaglutide, liraglutide requires daily rather than weekly injection and produces less weight loss (approximately 5-8% vs 15-17% body weight). It has a shorter half-life of 13 hours versus semaglutide's 7-day half-life, resulting in lower steady-state exposure. However, its longer track record provides greater long-term safety confidence for some clinicians.
Community Observations
Many users report that liraglutide's daily dosing allows more flexible appetite control timing compared to weekly injectables. The gradual dose titration schedule (0.6mg to 3.0mg over 4-5 weeks for obesity) helps mitigate GI side effects. Some practitioners still prefer it for patients who want the option to pause treatment quickly due to its shorter duration of action.
Media Vida
~13 hours
Reconstitución
Pre-filled pen (no reconstitution)
Almacenamiento
Liofilizado
Refrigerate 2-8C before first use.
Reconstituído
Room temperature or refrigerate. Use within 30 days.
Estado Legal EE.UU.
También Se Conoce Como
Última Investigación
Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.
Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.
Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.
Preguntas frecuentes
¿Qué es Liraglutide?
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, sharing 97% homology with native human GLP-1. It is FDA-approved as Victoza for type 2 diabetes management and as Saxenda for chronic weight management. As a once-daily injection, it was the first long-acting GLP-1 analog to achieve widespread clinical use and served as the predecessor to semaglutide.
¿Cómo funciona Liraglutide?
GLP-1 receptor agonist with 97% homology to native GLP-1. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying.
¿Cuál es el estado regulatorio de Liraglutide en EE. UU.?
FDA-approved (Rx only)
¿Cuál es la vida media de Liraglutide?
~13 hours
¿Qué otros nombres tiene Liraglutide?
Victoza, Saxenda
Peptide Contacts proporciona resúmenes basados en investigaciones únicamente para fines informativos. No hospedamos, distribuimos ni endosamos la documentación del proveedor. Todos los certificados de análisis, certificados GMP y comunicaciones del proveedor deben solicitarse y verificar directamente por el comprador. Nada en esta plataforma constituye asesoramiento legal, médico o profesional. Los usuarios son únicamente responsables de verificar las credenciales del proveedor y asegurarse de cumplir con todas las leyes locales, estatales y federales aplicables antes de comprar cualquier químico de investigación. El uso de esta plataforma constituye aceptación de toda la responsabilidad personal.
Leer aviso completo